Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost.

"Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The following authors are employees of GeneOne Life Science, Inc., the sponsor of the study and the developer of the GLS-5310 DNA vaccine against COVID-19 that is the subject of the paper. Christine R Roberts, Hyojin Lee, Areum Gil, Yeeun Oh, Ji eun Park, Bohyun Jeon, Ji Eun Lee, Deborah Kane, Sagar B Kudchodkar, Kar Muthumani, Young K Park *, Ijoo Kwon, Joel N Maslow *, * Young K Park and Joel N Maslow additionally own stock or stock options in GeneOne Life Science Inc. with a > $10,000 USD."

"5 Funding Study support was provided by the Korea Health Technology R&D Project through Korea Health Industry Development Institute (KHIDI), Ministry of Health and Welfare, Republic of Korea (grant HQ20C0040)."